Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: lopinavir; ritonavir

« Back to Dashboard

Summary for Generic Name: lopinavir; ritonavir

Tradenames:1
Patents:25
Applicants:1
NDAs:3
Drug Master File Entries: see list11
Suppliers: see list7
Therapeutic Class:Antivirals

Tentative approvals for LOPINAVIR; RITONAVIR

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL200MG; 50MG
<disabled><disabled>TABLET; ORAL200MG; 50MG
<disabled><disabled>TABLET; ORAL100MG; 25MG

Clinical Trials for: lopinavir; ritonavir

TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.
Status: Completed Condition: HIV

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers

Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Status: Completed Condition: Acquired Immunodeficiency Syndrome

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
Status: Completed Condition: HIV

Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
Status: Completed Condition: HIV-1 Infections

Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Status: Recruiting Condition: HIV

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes5,648,497*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Nov 9, 2007RXNo7,364,752*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Nov 9, 2007RXNo8,470,347*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
SOLUTION;ORAL021251Sep 15, 2000RXYes5,948,436*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes8,691,878*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc